Latest Articles

Publication Date
Efficacy of Organic Selenium Supplementation on Endometrioma Regression and Pain in Women With Endometriosis: A Triple-Blind Randomized Controlled Clinical Trial.

Endometriosis is a non-malignant, estrogen-dependent chronic inflammatory disorder that affects 10-15% of women during their reproductive years. Emerging evidence highlights the undeniable role of oxidative stress in the etiopathogenesis of …

Published: Oct. 10, 2025, midnight
The dual nature of immunotherapy in female reproductive disorders: immune homeostasis and clinical challenges.

The female reproductive system (FRS) exhibits unique immunological characteristics, balancing defense against pathogens with tolerance to sperm and semi-allogeneic embryos. Key players include decidual natural killer (dNK) cells, immune checkpoint …

Published: Oct. 2, 2025, midnight
Long-term health consequences of childhood adverse events: A narrative review.

"Adverse childhood events" or childhood adversity is a term often used to describe trauma and sources of stress during childhood or adolescence. Childhood adversity may negatively affect multiple aspects of …

Published: Sept. 26, 2025, midnight
Analyzing real-world adverse events of spironolactone with the FAERS database.

Spironolactone, a potassium-sparing diuretic, is commonly prescribed for conditions such as heart failure, hypertension, and hyperaldosteronism. This study aims to explore and analyze the safety profile of spironolactone by examining …

Published: Sept. 17, 2025, midnight
Efficacy of Elagolix and Relugolix for the Treatment of Pelvic Pain in Patients With Endometriosis: A Systematic Review.

Endometriosis is a chronic gynecological condition commonly associated with pelvic pain, dysmenorrhea, dyspareunia, and infertility. Owing to the limitations and adverse effects of traditional hormonal therapies, this study aimed to …

Published: Sept. 12, 2025, midnight
Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data.

Triptorelin, a gonadotropin-releasing hormone(GnRH) agonist, is approved by the US Food and Drug Administration(FDA) for treating advanced prostate cancer, endometriosis, and central precocious puberty(CPP) in children aged ≥ 2 years. …

Published: Sept. 1, 2025, midnight
Shaofu Zhuyu Decoction for Treating Endometriosis: A Systematic Review and Meta-Analysis.

Introduction: Shaofu Zhuyu Decoction (SZD) is a traditional Chinese herbal formula commonly used for gynecological disorders involving "blood stasis" and lower abdominal pain. Although applied clinically for endometriosis, evidence regarding …

Published: Aug. 29, 2025, midnight
Broad-Spectrum Adverse Events of Special Interests Based on Immune Response Following COVID-19 Vaccination: A Large-Scale Population-Based Cohort Study.

Background/Objectives: Current studies on adverse events related to the COVID-19 vaccine have predominantly focused on severe, life-threatening side effects. However, numerous less severe but common adverse events (AEs) remain underreported …

Published: March 6, 2025, midnight
Transfer of the Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix Into Breast Milk of Healthy Lactating Women.

Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the …

Published: Feb. 1, 2025, midnight
Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system.

Medroxyprogesterone acetate (MPA), a steroid progesterone, is widely used to treat endometriosis, menstrual disorders, and uterine bleeding in clinical practice. However, the safety profile of MPA requires comprehensive evaluation.

Published: Jan. 31, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!